# University of Michigan Rogel Cancer Center

Source: https://onco.cc/institutions/michigan-rogel/  
OnCo record `michigan-rogel` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Michigan's Rogel Cancer Center is home to the TMPRSS2-ERG discovery, MI-ONCOSEQ, and pioneering degrader chemistry (Wang).

## Summary

The University of Michigan Rogel Cancer Center in Ann Arbor holds NCI comprehensive designation and is home to the TMPRSS2-ERG discovery in prostate cancer, the MI-ONCOSEQ precision oncology sequencing programme, and pioneering targeted protein degradation chemistry. Arul M. Chinnaiyan's prostate genomics and Shaomeng Wang's MDM2 and BET degraders are its best-known contributions, with Eric R. Fearon, Max S. Wicha, Weiping Zou, Costas A. Lyssiotis and Lori J. Pierce among the people OnCo lists. OnCo links it to prostate cancer and to PROTACs and molecular glues. Whether degraders can reach targets that inhibitors could not, and do so safely, is the open question its chemistry programme faces. Its prostate genomics, degrader chemistry and precision oncology programmes are listed below.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Ann Arbor, MI, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://www.rogelcancercenter.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/University_of_Michigan_Rogel_Cancer_Center
- Official website: https://www.rogelcancercenter.org
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/)
- people: [Arul M. Chinnaiyan](https://onco.cc/people/arul-chinnaiyan/), [Costas A. Lyssiotis](https://onco.cc/people/costas-lyssiotis/), [Eric R. Fearon](https://onco.cc/people/eric-fearon/), [Lori J. Pierce](https://onco.cc/people/lori-pierce/), [Max S. Wicha](https://onco.cc/people/max-wicha/), [Richard Rogel](https://onco.cc/people/richard-rogel/), [Shaomeng Wang](https://onco.cc/people/shaomeng-wang/), [Theodore S. Lawrence](https://onco.cc/people/theodore-lawrence/), [Weiping Zou](https://onco.cc/people/weiping-zou/)
- key papers: [Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells](https://onco.cc/key-papers/paper-al-hajj-breast-cancer-stem-cells-pnas-2003/), [Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer](https://onco.cc/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/), [SU2C-PCF: integrative clinical genomics of advanced prostate cancer](https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/), [The mutational landscape of lethal castration-resistant prostate cancer](https://onco.cc/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/michigan-rogel.json